{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06340360",
            "orgStudyIdInfo": {
                "id": "23-358-06"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-509981-39",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Nektar Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)",
            "officialTitle": "A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled 60-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-phase-study-to-evaluate-rezpegaldesleukin-rezpeg-in-the-treatment-of-severe-to-very-severe-alopecia-areata-in-adult-patients-rezolve-aa"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-25",
            "studyFirstSubmitQcDate": "2024-03-25",
            "studyFirstPostDateStruct": {
                "date": "2024-04-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-18",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Nektar Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with severe to very severe alopecia areata.\n\nThe estimated duration includes a screening period of up to 35 days, a 36-week treatment period, and a 24-week follow-up period. The maximum study duration is approximately 65 weeks for all participants."
        },
        "conditionsModule": {
            "conditions": [
                "Alopecia Areata"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Patients will be randomized to 1 of 3 groups (low dose, high dose, or placebo).",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 110,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Low Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Rezpegaldesleukin Low Dose Every 2 weeks",
                    "interventionNames": [
                        "Drug: Rezpegaldesleukin"
                    ]
                },
                {
                    "label": "High Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Rezpegaldesleukin High Dose Every 2 weeks",
                    "interventionNames": [
                        "Drug: Rezpegaldesleukin"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo Every 2 weeks",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Rezpegaldesleukin",
                    "description": "Pharmaceutical form: Injection solution Route of administration: subcutaneous",
                    "armGroupLabels": [
                        "High Dose",
                        "Low Dose"
                    ],
                    "otherNames": [
                        "REZPEG",
                        "NKTR-358",
                        "LY3471851 (formerly)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Pharmaceutical form: Injection solution Route of administration: subcutaneous",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36",
                    "description": "The SALT score is the sum of percentage of hair loss in all areas with a maximum score of 100 (higher score indicates greater hair loss).",
                    "timeFrame": "Baseline and Week 36"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percent change from baseline in SALT score",
                    "description": "SALT score is the sum of percentage of hair loss in all areas with a maximum score of 100 (higher score indicates greater hair loss).",
                    "timeFrame": "Baseline and Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 52 and 60."
                },
                {
                    "measure": "Proportion of patients achieving improvement in Severity of Alopecia Tool (SALT) \u2265 50%/75%/90%",
                    "description": "Proportion of patients achieving improvement of \u2265 50%/75%/90% in Severity of Alopecia Tool (SALT) relative to their baseline score (SALT50/75/90). SALT score is the sum of percentage of hair loss in all areas with a maximum score of 100 (higher score indicates greater hair loss).",
                    "timeFrame": "Baseline and Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 52 and 60."
                },
                {
                    "measure": "Proportion of patients achieving an absolute SALT score \u2264 10/20/30/50",
                    "description": "Proportion of patients achieving an absolute SALT score of \u2264 10/20/30/50. SALT score is the sum of percentage of hair loss in all areas (higher score indicates greater hair loss). Total percentage of patients with absolute SALT score of \u2264 10/20/30/50 will be calculated.",
                    "timeFrame": "Baseline and Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 52 and 60."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults who are at least 18 years \u226460 years for males (\u226470 years of age for females) old at the time of informed consent\n* Diagnosis of Alopecia Areata (AA) severity at screening and baseline:\n\n  1. severe to very severe AA (\u2265 50% scalp involvement) as measured using the SALT score\n  2. Documented history over 6 months with no spontaneous improvement prior to baseline\n  3. Current episode of severe to very severe AA of less than 8 years\n* Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening and baseline.\n* While on investigational product and for at least 30 days after taking the last dose of investigational product (IP), WOCBP who engage in activity in which conception is possible must use approved contraceptive method(s). For male patient with partner that is WOCBP in which conception is possible, male patient must agree to use approved contraceptive method(s).\n* Able to complete patient questionnaires\n* Able and willing to comply with requested study visits and procedures\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Men and women (of reproductive potential) unwilling to use birth control and women who are pregnant or breastfeeding.\n* Patient has primarily \"diffuse\" type AA (characterized by diffuse hair shedding).\n* Presence of another form of alopecia.\n* Prior use of any of the following treatments:\n\n  1. aldesleukin\n  2. investigational IL-2 analog\n  3. oral Janus kinase (JAK) inhibitor for any indication, including, but not limited to, baricitinib, upadacitinib, abrocitinib, tofacitinib, and ruxolitinib, whether marketed or investigational\n  4. systemic immune-modulating biologic therapy (including, but not limited to, dupilumab, tralokinumab, lebrikizumab, nemolizumab, rocatinlimab, rituximab, ocrelizumab, ofatumumab, belimumab, daxdilimab, etc.) whether marketed or investigational\n* History of cancer or lymphoproliferative disease within 5 years prior to Day 1. Note: Patients with successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma with no evidence of metastatic disease for 3 years and/or localized carcinoma in situ of the cervix with no evidence of recurrence within the 3 years prior to Day 1 are not to be excluded.\n* Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C at screening.\n* Other skin conditions that would interfere with study assessments of AA",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "70 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nektar Recruitment",
                    "role": "CONTACT",
                    "phone": "8554828676",
                    "email": "StudyInquiry@nektar.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Study Director",
                    "affiliation": "Nektar Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Quest Dermatology Research",
                    "status": "RECRUITING",
                    "city": "Northridge",
                    "state": "California",
                    "zip": "91324",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.22834,
                        "lon": -118.53675
                    }
                },
                {
                    "facility": "Atlanta Biomedical Clinical Research",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30331",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Clinical Investigation Specialists, Inc.",
                    "status": "RECRUITING",
                    "city": "Gurnee",
                    "state": "Illinois",
                    "zip": "60031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.3703,
                        "lon": -87.90202
                    }
                },
                {
                    "facility": "Indiana Clinical and Translational Sciences Institute (CTSI) Clinical Research Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                },
                {
                    "facility": "Michigan Center for Skin Care Research",
                    "status": "RECRUITING",
                    "city": "Clinton Township",
                    "state": "Michigan",
                    "zip": "48038",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.58698,
                        "lon": -82.91992
                    }
                },
                {
                    "facility": "ALLCUTIS Research, LLC.",
                    "status": "RECRUITING",
                    "city": "Portsmouth",
                    "state": "New Hampshire",
                    "zip": "03801",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.07176,
                        "lon": -70.76255
                    }
                },
                {
                    "facility": "Sadick Research Group LLC",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10075",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "DermDox Centers for Dermatology",
                    "status": "RECRUITING",
                    "city": "Camp Hill",
                    "state": "Pennsylvania",
                    "zip": "17011",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.23981,
                        "lon": -76.91997
                    }
                },
                {
                    "facility": "North Texas Center for Clinical Research",
                    "status": "RECRUITING",
                    "city": "Frisco",
                    "state": "Texas",
                    "zip": "75034",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.15067,
                        "lon": -96.82361
                    }
                },
                {
                    "facility": "Austin Institute for Clinical Research",
                    "status": "RECRUITING",
                    "city": "Pflugerville",
                    "state": "Texas",
                    "zip": "786660",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.43937,
                        "lon": -97.62
                    }
                },
                {
                    "facility": "Enverus Medical Research",
                    "status": "RECRUITING",
                    "city": "Surrey",
                    "state": "British Columbia",
                    "zip": "V3V 0C6",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 49.10635,
                        "lon": -122.82509
                    }
                },
                {
                    "facility": "Lynderm Research Inc",
                    "status": "RECRUITING",
                    "city": "Markham",
                    "state": "Ontario",
                    "zip": "L3P 1X3",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.86682,
                        "lon": -79.2663
                    }
                },
                {
                    "facility": "The Centre for Clinical Trials",
                    "status": "RECRUITING",
                    "city": "Oakville",
                    "state": "Ontario",
                    "zip": "L6J 7W5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.45011,
                        "lon": -79.68292
                    }
                },
                {
                    "facility": "The Centre for Dermatology",
                    "status": "RECRUITING",
                    "city": "Richmond Hill",
                    "state": "Ontario",
                    "zip": "L4B 1A5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.87111,
                        "lon": -79.43725
                    }
                },
                {
                    "facility": "Centre de Recherche Saint-Louis SHERBROOKE",
                    "status": "RECRUITING",
                    "city": "Sherbrooke",
                    "state": "Quebec",
                    "zip": "J1G 1X9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.40008,
                        "lon": -71.89908
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000505",
                    "term": "Alopecia"
                },
                {
                    "id": "D000000506",
                    "term": "Alopecia Areata"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007039",
                    "term": "Hypotrichosis"
                },
                {
                    "id": "D000006201",
                    "term": "Hair Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000020763",
                    "term": "Pathological Conditions, Anatomical"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3846",
                    "name": "Alopecia",
                    "asFound": "Alopecia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3847",
                    "name": "Alopecia Areata",
                    "asFound": "Alopecia Areata",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10089",
                    "name": "Hypotrichosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M9293",
                    "name": "Hair Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22519",
                    "name": "Pathological Conditions, Anatomical",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}